Meticulous Research®—a leading market research company, published a research report titled, ‘Molecular Diagnostics Market by Product (Reagents & Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, ISH, INAAT, Sequencing, Microarray), Application (Infectious Diseases, Oncology), End User (Hospital, Diagnostic Lab) – Global Forecast to 2030.’
According to this latest publication from Meticulous Research®, the molecular diagnostics market is projected to reach $46.69 billion by 2030, at a CAGR of 5.6% from 2023 to 2030. The rising global geriatric population, the increasing prevalence of communicable & non-communicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures are the factors contributing to the growth of this market. Additionally, the growing scope in emerging countries, increasing focus on companion diagnostics, and the rising popularity of direct-to-consumer (DTC) genetic testing are expected to offer significant growth opportunities for the players operating in the molecular diagnostics market.
Increase in Approvals of Molecular Diagnostics Products During the COVID-19 Pandemic
Amid the pandemic, manufacturers focused on developing various diagnostic kits and assays for early disease diagnosis, which is expected to drive the molecular diagnostics market in the coming years. Some of the companies that launched their diagnostic products during the pandemic are mentioned below-
- In May 2022, Cepheid (a subsidiary of Danaher) (U.S.) received CE Mark for Xpert Xpress CoV-2 plus. The test is for the qualitative detection of COVID-19.
- In May 2021, F. Hoffmann-La Roche Ltd (Switzerland) received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for cobas SARS-CoV-2 test for individuals without symptoms or reasons to suspect COVID-19.
- In November 2020, BioMérieux S.A. (France) received the CE mark for the SARS-CoV-2 R-GENE test. The test is part of the ARGENE range for the detection of SARS-CoV-2.
- In September 2020, Hologic, Inc. (U.S.) received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for asymptomatic COVID-19 testing with Panther Fusion SARS-CoV-2 Assay.
Download Free Report Sample Now : https://www.meticulousresearch.com/download-sample-report/cp_id=5375
With the increase in approvals, the companies operating in the diagnostics market also conducted web meetings and webinars to interact with customers & shareholders to provide product descriptions and customer demonstrations. This helped the end users know about the product in detail.
The molecular diagnostics market is segmented by Product & Service (Kits & Reagents, Instruments, Software & Services); Test Type [Laboratory Tests, Point-of-Care (PoC) Tests]; Technology [Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT), Microarrays, Mass Spectrometry, Sequencing, Other Technologies]; Application [Infectious Diseases (COVID-19, Hepatitis, HIV, Healthcare-associated Infections (HAIs), Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG), Human papillomavirus (HPV), Tuberculosis, Influenza, Other Infectious Diseases), Oncology (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Lymphoma, Leukemia, Cervical Cancer, Other Cancer Types), Genetic Testing, Neurological Diseases, Cardiovascular Diseases, Other Applications]; End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Other End Users); and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.
Based on product & service, in 2023, the kits & reagents segment is expected to account for the largest share of the molecular diagnostics market. Factors contributing to the large market share of this segment are the frequent and repetitive use of diagnostic kits, the large portfolio of disease-specific kits for the early diagnosis of chronic and infectious diseases, and technological advancements in molecular diagnostics.
Speak to Analyst : https://www.meticulousresearch.com/speak-to-analyst/cp_id=5375
Based on test type, in 2023, the laboratory tests segment is expected to account for the largest share of the molecular diagnostics market. The large market share of this segment is attributed to a large number of lab tests, as these are preferred by hospitals, laboratories, and academic & research institutes. Additionally, the majority of the developments have been done in lab tests.
Based on technology, in 2023, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the molecular diagnostics market. PCR is a sensitive technique that allows rapid amplification of a specific segment of DNA. This technology thus helps in the diagnosis of diseases. It is effective for low-number targets and less expensive than other technologies, such as sequencing. Hence, the huge demand for PCR devices further contributes to the growth of this segment.
Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the molecular diagnostics market. The large market share of this segment is attributed to the rising incidence rates of infectious diseases and the increase in initiatives by government organizations toward their prevention by early diagnosis.
Based on end user, the molecular diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, academic & research institutes, and other end users. In 2023, the hospitals & clinics segment is expected to account for the largest share of the molecular diagnostics market. Hospitals & clinics perform a wide range of tests to diagnose various medical conditions, including communicable and non-communicable diseases and other medical conditions to ensure proper clinical planning of treatment and prevention. Thus, the large number of patients going to hospitals & clinics contributes to the large market share of this segment.
This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa. In 2023, North America is expected to account for the largest share of the molecular diagnostics market, followed by Europe and Asia-Pacific. Highly developed infrastructure for diagnostics research, favorable reimbursement policies, increased accessibility to healthcare, and the high number of laboratory tests performed annually contribute to the large market share of this region.
The key players operating in the molecular diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), and Seegene, Inc. (South Korea).
Quick Buy Now: https://www.meticulousresearch.com/Checkout/64888954
Key questions answered in the report-
- Which are the high-growth market segments in terms of product & service, test type, technology, application, end user, and geography?
- What was the historical market for molecular diagnostics across the globe?
- What are the market forecasts and estimates for the period 2023–2030?
- What are the major drivers, restraints, opportunities, and challenges in the molecular diagnostics market?
- Who are the major players in the molecular diagnostics market?
- What is the competitive landscape, and who are the market leaders in the molecular diagnostics market?
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research